GLAND Stock Overview
Engages in manufacturing and sale of injectable formulation in India, the United States, Europe, Canada, Australia, New Zealand, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Gland Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,850.35 |
| 52 Week High | ₹2,194.00 |
| 52 Week Low | ₹925.10 |
| Beta | 0.36 |
| 1 Month Change | 9.72% |
| 3 Month Change | 5.38% |
| 1 Year Change | 97.85% |
| 3 Year Change | -40.67% |
| 5 Year Change | n/a |
| Change since IPO | 1.69% |
Recent News & Updates
Recent updates
Earnings Miss: Gland Pharma Limited Missed EPS By 15% And Analysts Are Revising Their Forecasts
May 25
Is Gland Pharma (NSE:GLAND) A Risky Investment?
Mar 19Gland Pharma Limited's (NSE:GLAND) Share Price Matching Investor Opinion
Feb 16Analysts' Revenue Estimates For Gland Pharma Limited (NSE:GLAND) Are Surging Higher
May 20Is Gland Pharma Limited (NSE:GLAND) Expensive For A Reason? A Look At Its Intrinsic Value
Feb 07Analysts Just Slashed Their Gland Pharma Limited (NSE:GLAND) EPS Numbers
Jul 22Does This Valuation Of Gland Pharma Limited (NSE:GLAND) Imply Investors Are Overpaying?
Jul 14Is Now The Time To Put Gland Pharma (NSE:GLAND) On Your Watchlist?
Feb 08A Look At The Intrinsic Value Of Gland Pharma Limited (NSE:GLAND)
Jul 05Gland Pharma (NSE:GLAND) Strong Profits May Be Masking Some Underlying Issues
May 24Gland Pharma Limited (NSE:GLAND) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
May 19Gland Pharma Limited's (NSE:GLAND) 27% Price Boost Is Out Of Tune With Earnings
Mar 04Gland Pharma Limited's (NSE:GLAND) Stock Is Going Strong: Is the Market Following Fundamentals?
Feb 20Shareholder Returns
| GLAND | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -0.9% | -1.8% | -1.9% |
| 1Y | 97.8% | 51.6% | 41.0% |
Return vs Industry: GLAND exceeded the Indian Pharmaceuticals industry which returned 51.6% over the past year.
Return vs Market: GLAND exceeded the Indian Market which returned 41% over the past year.
Price Volatility
| GLAND volatility | |
|---|---|
| GLAND Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.5% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: GLAND has not had significant price volatility in the past 3 months.
Volatility Over Time: GLAND's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 4,752 | Srinivas Sadu | www.glandpharma.com |
Gland Pharma Limited engages in manufacturing and sale of injectable formulation in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical API products including synthesis of complex drug molecules, such as LMWH, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro intestinal, gynecological, hormones, neuro/Cns, ophthal/ontological, and other areas, as well as pain and analgesics, respirator, and vitamins, minerals and nutrients; and offers contract development services.
Gland Pharma Limited Fundamentals Summary
| GLAND fundamental statistics | |
|---|---|
| Market cap | ₹303.09b |
| Earnings (TTM) | ₹7.72b |
| Revenue (TTM) | ₹58.35b |
39.5x
P/E Ratio5.2x
P/S RatioIs GLAND overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLAND income statement (TTM) | |
|---|---|
| Revenue | ₹58.35b |
| Cost of Revenue | ₹24.03b |
| Gross Profit | ₹34.32b |
| Other Expenses | ₹26.59b |
| Earnings | ₹7.72b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 46.90 |
| Gross Margin | 58.82% |
| Net Profit Margin | 13.24% |
| Debt/Equity Ratio | 3.7% |
How did GLAND perform over the long term?
See historical performance and comparison